---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-097036"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:23:33.722895+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tivic Health Q2 2024 revenue $140K, net loss $1.3M; Phase 1 VNS results, cost cuts

## Summary
- Q2 2024 revenue $140K vs $203K in Q2 2023; H1 2024 revenue $474K, down 12% YoY.
- Net loss Q2 2024 $1.3M vs $2.1M; H1 net loss $2.7M, $1.5M improvement from H1 2023.
- Gross margin improved to 42% in H1 2024 from 32% in H1 2023 due to cost reductions.
- Cash and equivalents $3.7M as of June 30, 2024; raised $3.3M net from May 2024 offering.
- Phase 1 VNS trial results with Feinstein Institutes; ClearUP 2.0 launched; lease and logistics savings.

## SEC filing metadata
- accession: 0000950170-24-097036
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017024097036/0000950170-24-097036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017024097036/tivc-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-097036
- JSON: https://secwatch.observer/filing/0000950170-24-097036.json
- Plain text: https://secwatch.observer/filing/0000950170-24-097036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.